Jessica Hill
Adult Health · Marion, VANPI 1427372788
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,821 of the $4,266 with a category attached, or 89.6%. It is spread thinly across 41 manufacturers, the largest accounting for just 11.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,528, 3.2 times the $472 reported in 2021.
Across 121 payments — averaging $35.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$487
- Incyte Corporation$379
- Daiichi Sankyo Inc.$348
- AbbVie$319
- Novartis$296
- Lilly USA, LLC$248
- plus $2K from 35 others
What the payments were for
- Food & beverage$3,82190%
- Education$3618%
- Other$832%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 9 | $487 |
| Incyte Corporation | 10 | $379 |
| Daiichi Sankyo Inc. | 5 | $348 |
| AbbVie | 7 | $319 |
| Novartis | 10 | $296 |
| Lilly USA, LLC | 5 | $248 |
| Genentech USA, Inc. | 7 | $207 |
| AstraZeneca | 4 | $168 |
| Bristol Myers Squibb | 3 | $161 |
| Merck | 6 | $132 |
| Astellas Pharma US Inc | 5 | $128 |
| Regeneron Healthcare Solutions, Inc. | 1 | $127 |
| Gilead | 1 | $125 |
| Pfizer | 5 | $122 |
| Ipsen Biopharmaceuticals, Inc | 4 | $118 |
| GSK | 3 | $91 |
| Beigene USA, Inc. | 4 | $75 |
| ADC Therapeutics America, Inc. | 3 | $62 |
| Abbott | 1 | $57 |
| Genmab U.S., Inc. | 2 | $48 |
| Servier Pharmaceuticals LLC | 2 | $46 |
| Jazz Pharmaceuticals Inc. | 2 | $46 |
| Johnson & Johnson | 2 | $41 |
| Bayer | 2 | $39 |
| Array Biopharma Inc | 2 | $37 |
| Alnylam Pharmaceuticals Inc. | 1 | $30 |
| Deciphera Pharmaceuticals Inc. | 1 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Amgen | 1 | $24 |
| Syndax Pharmaceuticals, Inc. | 1 | $24 |
| Sobi, Inc | 1 | $23 |
| Tempus AI, Inc | 1 | $23 |
| Eisai Inc. | 1 | $23 |
| Adaptive Biotechnologies Corporation | 1 | $23 |
| Boehringer Ingelheim | 1 | $22 |
| Stemline Therapeutics Inc. | 1 | $22 |
| Beone Medicines USA, Inc. | 1 | $21 |
| Caris MPI, Inc. | 1 | $20 |
| Taiho Oncology, Inc. | 1 | $20 |
| Puma Biotechnology, Inc. | 1 | $18 |
| Tersera Therapeutics LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,266 in reported general payments places this provider in the 85th percentile of 368 adult health providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 24 | $15,352 |
| OxycontinOxycodone Hcl | 11 | $11,917 |
| Ondansetron Hcl | 98 | $7,162 |
| Oxycodone Hcl | 104 | $1,710 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 34 | $956 |
| Prochlorperazine Maleate | 63 | $862 |
| Letrozole | 44 | $519 |
| Gabapentin | 36 | $422 |
| Ondansetron OdtOndansetron | 25 | $414 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 14 | $294 |
| Hydroxyurea | 18 | $290 |
| Anastrozole | 25 | $250 |
| Dexamethasone | 11 | $246 |
| Acyclovir | 29 | $217 |
| Potassium Chloride | 24 | $210 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $122 | $15,35224 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 368 adult health providers in Virginia.
Other adult health in Marion
- Christine KesslerFort Belvoir$107K
- Denise BruenCharlottesville$45K
- Theresa Harrington StukusFairfax$40K
- Chelsea KoskovichFredericksburg$34K
- Brittany BrownLynchburg$14K
- Colleen DieringVirginia Beach$13K
- Veronica HughesRichmond$12K
- Nicole SellersNorfolk$12K
- Amy WenzelMechanicsville$11K
- Robert GrossmanDanville$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.